Salbutamol Sulfate

• STOP-COPD Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Not authorised
  2022-500816-21-00 Phase IV 1 country Præhospitalet
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Not authorised
  2023-503693-20-00 Phase III 1 country Areteia Therapeutics Inc.
• A randomized, double-blind, placebo-controlled clinical endpoint bioequivalence study to evaluate the therapeutic equivalence and safety of … Not authorised
  2025-521565-27-00 Phase III 1 country Sandoz Private Limited
• A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf… Pending
  2025-521230-29-00 Phase III 1 country LETI Pharma S.L.U.
• Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT Pending
  2025-522694-11-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 Phase II 14 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti… Recruiting
  2024-517991-39-00 Phase III 6 countries Teva Branded Pharmaceutical Products R&D LLC
• Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort… Recruiting
  2024-519116-14-00 Phase II 5 countries AstraZeneca AB
• STOP-COPD Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Recruiting
  2022-502003-30-00 Phase IV 1 country Præhospitalet
• Effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure Recruiting
  2024-519513-61-00 Phase IV 1 country Hospital General Universitario Gregorio Maranon
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended
  2023-505435-12-00 Phase III 12 countries Teva Branded Pharmaceutical Products R&D LLC
• A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended
  2023-509001-76-00 Phase III 5 countries Glaxosmithkline Research & Development Limited
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 Phase III 9 countries Areteia Therapeutics Inc.
• A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (ClairaflyTM) Ended
  2022-502835-21-00 Phase II 6 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled … Ended
  2022-502854-16-00 Phase II 3 countries Rapt Therapeutics Inc.
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503572-24-00 Phase III 6 countries AstraZeneca AB
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 Phase III 11 countries AstraZeneca AB
• Evaluation of frequency occurrence persistent pulmonary hypertension of newborns treated by salbutamol Ended
  2024-515216-46-00 Phase III/IV 1 country Medical University Of Warsaw
• InSaKa trial: Insulin dextrose infusion versus nebulized salbutamol versus combination of salbutamol and insulin dextrose in acute hyperkale… Ended
  2024-514889-40-00 Phase IV 1 country Centre Hospitalier Universitaire De Nantes
• Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa) (NOPA) Ended
  2023-508706-23-00 Phase I/II 3 countries Thirty Respiratory Limited
• WALKALS : A pilot phase II study to evaluate the effect of salbutamol on walking capacity in ambulatory ALS patients. Expired
  2022-501624-14-00 Phase II 1 country Assistance Publique Hopitaux De Paris

Showing 1–21 of 21 trials